ストックスクリーナーアプリを入手
7.93
0.25%
0.010
アフターアワーズ：
7.94
0.01
+0.13%
Zevra Therapeutics Inc (ZVRA) 最新ニュース
Zevra Therapeutics Stock: A Deep Dive Into Analyst Perspectives (5 Ratings) - Benzinga
Canaccord raises Zevra Therapeutics target to $25; Keeps Buy rating - Investing.com India
Canaccord raises Zevra Therapeutics target to $25; Keeps Buy rating By Investing.com - Investing.com South Africa
Zevra Therapeutics Full Year 2024 Earnings: Revenues Beat Expectations, EPS Lags - Yahoo Finance
Zevra Therapeutics’ Earnings Call Highlights Success and Growth - TipRanks
Cantor Fitzgerald maintains $25 target on Zevra Therapeutics stock - Investing.com
Zevra Therapeutics stock target raised to $18 at JMP - Investing.com India
Zevra Therapeutics, Inc. (NASDAQ:ZVRA) Q4 2024 Earnings Call Transcript - Insider Monkey
Cantor Fitzgerald maintains $25 target on Zevra Therapeutics stock By Investing.com - Investing.com South Africa
Zevra Therapeutics stock target raised to $18 at JMP By Investing.com - Investing.com South Africa
Zevra Therapeutics Inc (ZVRA) Q4 2024 Earnings Call Highlights: Record Revenue and Strategic ... - Yahoo Finance
Zevra Therapeutics, Inc. (NASDAQ:ZVRA) Given Average Recommendation of “Buy” by Analysts - Defense World
Zevra Therapeutics Inc (ZVRA) Q4 2024 Earnings Call Highlights: Record Revenue and Strategic Expansion Plans - GuruFocus.com
Zevra Therapeutics: Strong Financial Performance and Strategic Growth Justify Buy Rating - TipRanks
Zevra Therapeutics Reports 2024 Financial Results and Strategic Progress - TipRanks
Zevra Therapeutics: Q4 Earnings Snapshot - mySA
ZEVRA THERAPEUTICS Earnings Results: $ZVRA Reports Quarterly Earnings - Nasdaq
Zevra Therapeutics (ZVRA) Reports Q4 Loss, Tops Revenue Estimates - Yahoo Finance
Earnings call transcript: Zevra Therapeutics Q4 2024 reports wider losses - Investing.com
Earnings call transcript: Zevra Therapeutics Q4 2024 reports wider losses By Investing.com - Investing.com UK
Zevra Therapeutics: Q4 Earnings Snapshot -March 11, 2025 at 05:23 pm EDT - Marketscreener.com
Zevra Therapeutics Q4 Net Loss Widens, Revenue Decreases; Shares Fall After Hours - Marketscreener.com
Zevra Therapeutics Inc reports results for the quarter ended December 31Earnings Summary - TradingView
Zevra Reports Full Year 2024 and Fourth Quarter Financial Results - GlobeNewswire
Zevra Earnings: Q4 Revenue Surges to $12M as MIPLYFFA Launch Gains Traction - StockTitan
Investors Appear Satisfied With Zevra Therapeutics, Inc.'s (NASDAQ:ZVRA) Prospects - Simply Wall St
Zevra Therapeutics (ZVRA) Expected to Announce Earnings on Tuesday - Defense World
Rhumbline Advisers Has $568,000 Position in Zevra Therapeutics, Inc. (NASDAQ:ZVRA) - Defense World
Zevra at TD Cowen Conference: Strategic Shifts in Rare Disease Focus - Investing.com
(ZVRA) Long Term Investment Analysis - Stock Traders Daily
Investing in Zevra Therapeutics (NASDAQ:ZVRA) five years ago would have delivered you a 83% gain - Yahoo Finance
Zevra Launches New Disease State Awareness Campaign, ‘Learn NPC, Read Between the Signs,’ to Drive Early Recognition and Treatment of Niemann-Pick Disease Type C - The Globe and Mail
Watkins Represents Zevra Therapeutics in Agreement to Sell Its Rare Pediatric Disease Priority Review Voucher - Latham & Watkins LLP
Zevra Seals PRV Sale And Banks $150m - Citeline News & Insights
Zevra Therapeutics: Strategic Growth and Financial Strength Drive Buy Rating - TipRanks
Zevra Launches New Disease State Awareness Campaign, ‘Learn - GlobeNewswire
Zevra Launches New Disease State Awareness Campaign, 'Learn NPC, Read Between the Signs,' to Drive Early Recognition and Treatment of Niemann-Pick Disease Type C - The Manila Times
Zevra sells priority review voucher for $150m to support drug launches - Pharmaceutical Technology
Rare Disease Biotech Zevra Therapeutics to Sell FDA Drug Review Fast Pass for $150M - MedCity News
Zevra Therapeutics rises on agreement to sell its FDA priority review voucher for $150 mln - TradingView
Zevra Therapeutics Enters Agreement to Sell its Rare Pediatric Disease Priority Review Voucher for $150 Million - GlobeNewswire
BRIEF—Zevra sells Miplyffa-linked PRV for $150 million - The Pharma Letter
Zevra Therapeutics to Sell Priority Review Voucher for $150 Million -February 27, 2025 at 11:12 am EST - Marketscreener.com
Zevra Therapeutics to Sell Priority-Review Voucher for $150 Million - MarketWatch
Zevra Therapeutics Sells Priority Review Voucher for $150M - TipRanks
Zevra Therapeutics stock rises on $150M asset sale By Investing.com - Investing.com Canada
Zevra Therapeutics stock rises on $150M asset sale - Investing.com
Zevra Therapeutics Enters Agreement to Sell its Rare Pediatric Disease Priority Review Voucher for $150 Million - Benzinga
How Will Zevra Use Its Massive $150M Windfall? Non-Dilutive Funding Fuels Rare Disease Strategy - StockTitan
ZEVRA THERAPEUTICS Earnings Preview: Recent $ZVRA Insider Trading, Hedge Fund Activity, and More - Nasdaq
Zevra to Report 2024 Fourth Quarter and Full Year Financial Results - The Manila Times
When Will Zevra Reveal Its 2024 Financial Performance? Key Date for Rare Disease Investors - StockTitan
Zevra to Participate at Upcoming Investor Conferences - The Manila Times
Rare Disease Pioneer Zevra Sets Stage for Major Healthcare Conference Double-Header - StockTitan
Insider Selling: Zevra Therapeutics, Inc. (NASDAQ:ZVRA) CFO Sells 11,000 Shares of Stock - MarketBeat
Zevra therapeutics CFO sells shares for $86,471 - MSN
Zevra Therapeutics exec sells $23,587 in stock - MSN
Neil F. Mcfarlane Sells 61,273 Shares of Zevra Therapeutics, Inc. (NASDAQ:ZVRA) Stock - MarketBeat
Zevra Therapeutics, Inc. (NASDAQ:ZVRA) SVP Timothy J. Sangiovanni Sells 3,000 Shares - MarketBeat
5.68%
0.28%
大文字化:
|
ボリューム (24 時間):